公开(公告)号：EP2865680A1

公开(公告)日：2015-04-29

申请号：EP13806818.4

申请日：2013-05-15

申请人： Chengdu Easton Pharmaceutical Co., Ltd.

发明人： WANG, Ying ,  XIANG, Yongzhe ,  CEN, Guodong ,  HUANG, Long ,  LIU, Jian ,  ZHOU, Ning ,  ZHANG, Jibing

IPC分类号： C07D473/04 ,  A61K31/437 ,  A61K31/522 ,  A61P3/10

CPC分类号： C07D473/08 ,  A61K31/437 ,  A61K31/522 ,  C07D473/06

摘要： The present invention discloses a xanthine derivative having the structure of the following general formula (I) or a pharmaceutically acceptable salt thereof; further discloses a preparation method for the xanthine derivative or a pharmaceutically acceptable salt thereof; and further discloses the use of the xanthine derivative or a pharmaceutically acceptable salt thereof. Through experiments of DPP-IV activity inhibition experiments in vitro, impact on glucose tolerance in normal mice and impact on blood glucose in spontaneous diabetic mice, it proves that the compounds and pharmaceutically acceptable salts thereof show good DPP-IV inhibition activity, can be applied to prepare medicines for treating dipeptidyl peptidase IV-related diseases, and more particularly, can be applied to the use of medicines for treating type II diabetes or diseases of abnormal glucose tolerance.

摘要翻译： 本发明公开了具有以下通式（I）结构的黄嘌呤衍生物或其药学上可接受的盐; 进一步公开了黄嘌呤衍生物或其药学上可接受的盐的制备方法; 并进一步公开了黄嘌呤衍生物或其药学上可接受的盐的用途。 通过体外DPP-IV活性抑制实验，正常小鼠对葡萄糖耐量的影响及对自发性糖尿病小鼠血糖的影响实验，证明该化合物及其药学上可接受的盐具有良好的DPP-IV抑制活性，可应用于 制备治疗二肽基肽酶IV相关疾病的药物，更具体地说，可以应用于治疗II型糖尿病或葡萄糖耐量异常疾病的药物。